ImmunoPrecise Antibodies Ltd. products

Human placenta type alkaline phosphatase is a dimeric glycoprotein (N-linked glycans at asparagine residues 144 and 271). The protein is bound to the cell-membrane via a GPI-anchor which is linked to Aspartate 506.

Human placenta type alkaline phosphatase is a dimeric glycoprotein (N-linked glycans at asparagine residues 144 and 271). The protein is bound to the cell-membrane via a GPI-anchor which is linked to Aspartate 506.

Human ACE-2 (angiotensin-converting enzyme 2) belongs to the angiotensin-converting enzyme family of dipeptidyl carboxydipeptidases and has considerable homology to human angiotensin 1 converting enzyme. This secreted protein catalyzes the cleavage of angiotensin I into angiotensin 1-9, and angiotensin II into the vasodilator angiotensin 1-7. The organ- and cell-speci c expression of this gene suggests that it may play a role in the regulation of cardiovascular and renal function, as well as fertility. In addition, the encoded protein is a functional receptor for the spike glycoprotein of the human coronavirus HCoV-NL63 and the human severe acute respiratory syndrome coronaviruses, SARS-CoV and SARS-CoV-2 (COVID-19 virus).

Human ACE-2 (angiotensin-converting enzyme 2) belongs to the angiotensin-converting enzyme family of dipeptidyl carboxydipeptidases and has considerable homology to human angiotensin 1 converting enzyme. This secreted protein catalyzes the cleavage of angiotensin I into angiotensin 1-9, and angiotensin II into the vasodilator angiotensin 1-7. The organ- and cell-speci c expression of this gene suggests that it may play a role in the regulation of cardiovascular and renal function, as well as fertility. In addition, the encoded protein is a functional receptor for the spike glycoprotein of the human coronavirus HCoV-NL63 and the human severe acute respiratory syndrome coronaviruses, SARS-CoV and SARS-CoV-2 (COVID-19 virus).

Our genetic immunization protocols have proven successful in the generation of monoclonal antibodies against new, challenging, and conformation-sensitive targets, and have been successfully applied in transgenic animals. Through our proprietary vectors, our algorithm-based protocols produce native protein with appropriate post-translational modifications in vivo and provide very high transfection efficiency. We recommend this technology for complex protein classes, including GPCRs and ion channels as it bypasses the requirement to produce difficult recombinant proteins, and overcomes conformational obstacles of such antigens. Our vectors are developed in-house and not subject to downstream milestones and royalties.

Rapid Prime identifies positive monoclonal antibodies in as little as 32 days. This method is especially beneficial for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. Other sources of immunogens include conserved or smaller proteins, peptides, and whole cell bacteria. After the immunization of rodents, we apply our proprietary electrofusion or PEG-fusion to generate hybridomas. The subsequent cloning, using semi-solid media and clone picking to accelerate the process, allows us to identify monoclonal antibody producing hybridoma cells, fast. Rapid Prime immunization can also be combined with B cell Select or Phage Display.

Immunization of multiple species with a syngeneic cell line. After the selection of the species for the immunization, we discuss a suitable cell line and prepare transfected cells for immunization and screening.

c

Noggin-Fc Fusion Protein Conditioned Medium. Production platform: This product has been produced in HEK293 cells using the rPEx®; recombinant protein production platform.